TARGESOME

Pharmaceutical preparations that aid in the transport and delivery of diagnostic, therapeutic and imaging agents for the treatment of tumor metastasis, solid tumor growth, osteoporosis, Paget's disease, humoral hyperglycemia of malignancy, angiogenesis, including tumor angiogenesis, retinopathy, macular degeneration, arthritis, including rheumatoid arthritis, periodontal disease, psoriasis and smooth muscle cell migration, diseases associated with neovascular growth, namely, solid tumors, blood borne tumors, leukemia, tumor metastastasis, benign tumors, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, chronic inflammation, ocular angiogenic diseases, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrome, myocardial angiogenesis, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma, and wound granulation, diseases of excessive or abnormal stimulation of endothelial cells, namely, intestinal adhesions, atherosclerosis, restenosis, scleroderma, and hypertrophic scars

Medical devices, namely, polymerized nanoparticles for the transport and delivery of diagnostic, therapeutic and imaging agents